Filing Flows › Tango Therapeutics (TNGX) › Q2 2025 › vs Q1 2025
Tango Therapeutics (TNGX) Q2 2025 vs Q1 2025 (quarter over quarter)
Tango Therapeutics's revenue fell $2.2M (-41%) from $5.4M in Q1 2025 to $3.2M in Q2 2025.
Tango Therapeutics, Q2 2025: revenue $3.2M (-84% year over year), net loss $38.9M, operating cash flow −$36.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q2 2025 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $5.4M | −$2.2M | -41% |
| Other income, net | $2.1M | $2.7M | −$539K | -20% |
| Net loss | $38.9M | $39.9M | −$1.0M | -3% |
| Costs & expenses | $44.2M | $48.0M | −$3.8M | -8% |
| Operating costs | $44.1M | $47.9M | −$3.8M | -8% |
| Income tax | $35K | $34K | $1K | +3% |
| Research & development | $32.8M | $36.4M | −$3.6M | -10% |
| General & admin | $11.3M | $11.5M | −$139K | -1% |
| Operating cash sources | $43.7M | $49.6M | −$5.9M | -12% |
| Depreciation | $625K | $622K | $3K | +0.5% |
| Share-based compensation | $6.6M | $7.3M | −$685K | -9% |
| Cash used in operations | $36.5M | $41.7M | −$5.2M | -12% |
| Net loss absorbed | $38.9M | $39.9M | −$1.0M | -3% |
| Working capital & other | $4.9M | $9.7M | −$4.8M | -50% |
Questions
How much did Tango Therapeutics's revenue grow quarter over quarter in Q2 2025?
Tango Therapeutics's revenue fell $2.2M (-41%) from $5.4M in Q1 2025 to $3.2M in Q2 2025.